Hoogstraten M C, van der Ploeg R J, vd Burg W, Vreeling A, van Marle S, Minderhoud J M
Department of Neurology, University Hospital, Groningen, The Netherlands.
Acta Neurol Scand. 1988 Mar;77(3):224-30. doi: 10.1111/j.1600-0404.1988.tb05899.x.
Sixteen patients suffering from spasticity due to multiple sclerosis were treated with baclofen and tizanidine in a partially blind cross-over study. No significant difference in efficacy was found. The most striking difference was seen in the side-effects: baclofen frequently caused more or less severe muscle weakness and even falling during walking and standing. Treatment with tizanidine produced an apparent improvement of mobility in some patients suffering from moderate or marked paresis associated with a marked spasticity of their legs. Isometric muscle strength did not show any significant changes during either treatment. The different impact of baclofen and tizanidine on mobility and weight support seems to be related to their different site of action in spasticity.
在一项部分盲法交叉研究中,对16名因多发性硬化症而患有痉挛的患者使用巴氯芬和替扎尼定进行治疗。未发现疗效有显著差异。最显著的差异体现在副作用方面:巴氯芬经常或多或少地导致严重的肌肉无力,甚至在行走和站立时跌倒。替扎尼定治疗使一些患有中度或明显轻瘫且伴有腿部明显痉挛的患者的活动能力有明显改善。在两种治疗过程中,等长肌力均未显示出任何显著变化。巴氯芬和替扎尼定对活动能力和体重支撑的不同影响似乎与其在痉挛中的不同作用部位有关。